Progress of lenalidomide in treatment of non-Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2019.03.016
- VernacularTitle:来那度胺治疗非霍奇金淋巴瘤研究进展
- Author:
Xuehan MAO
1
;
Lugui QIU
;
Gang AN
Author Information
1. 中国医学科学院北京协和医学院血液学研究所血液病医院 实验血液学国家重点实验室
- Keywords:
Lymphoma,non-Hodgkin;
Lenalidomide;
Treatment
- From:
Journal of Leukemia & Lymphoma
2019;28(3):185-189
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,several large-scale clinical trials have confirmed that lenalidomide has a certain role in the treatment of non-Hodgkin lymphoma (NHL).Currently,the latest edition of the National Comprehensive Cancer Network (NCCN)guideline (2018.V3) recommend that lenalidomide could be used for multiple subtypes of NHL including diffuse large B-cell lymphoma,mantle cell lymphoma,follicular lymphoma,and marginal zone lymphoma.This article reviews the progress in the application of lenalidomide in NHL.
